Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPBRANCO, Klebia CastelloAZEKA, EstelaJATENE, MarceloTRINDADE, EvelindaGALAS, Filomena Regina Barbosa GomesHAJJAR, Ludhmila AbrahaoBENVENUTI, LuizRISO, ArlindoTANAMATI, CarlaPENHA, JulianoAULER JUNIOR, Jose Otavio CostaATIK, Edmar2013-10-112013-10-112013PEDIATRIC TRANSPLANTATION, v.17, n.2, p.193-193, 20131397-3142https://observatorio.fm.usp.br/handle/OPI/2757OBJETIVE: The aim of this study was to evaluate the clinical outcome of children undergoing heart transplantation who required conversion from a cyclosporine-based steroid free therapy to a tacrolimus-based immunosuppressive regimen. MATERIAL AND METHODS: We performed a prospective observational cohort study in 28 children who underwent conversion from a cyclosporine- based steroid free therapy to a tacrolimus-based therapy for refractory or late rejection or intolerance to cyclosporine. RESULTS: There was complete resolution of refractory rejection episodes and adverse side effects in all patients. The incidence rate (x100) of rejection episodes before and after conversion was 7.98 and 2.11, respectively (p≤0.0001). Actuarial 1 month, 1 and 5 yr survival, in patients converted to tacrolimus was 100%, 96% and 85.5% respectively. CONCLUSION: Tacrolimus is effective as rescue therapy for refractory rejection and is a Terapeutic option for pediatric patients.engrestrictedAccessconferenceObjectCopyright WILEY-BLACKWELL10.1111/petr.12037PediatricsTransplantation